Compass Therapeutics receives Nasdaq notice over minimum bid price deficiency

PUBT · 17h ago
Compass Therapeutics receives Nasdaq notice over minimum bid price deficiency
  • Compass Therapeutics received a Nasdaq deficiency notice November 19, 2026, for closing bids below $1 for 30 consecutive business days.
  • The notice has no immediate listing impact; common stock continues trading on the Nasdaq Capital Market under CMPX.
  • The company has 180 calendar days, until May 18, 2027, to regain compliance with Nasdaq's minimum bid price requirement.
  • Compliance requires closing bids of at least $1 for a minimum of 10 consecutive business days before the deadline.
  • A conditional second 180-day compliance period may avert delisting; potential remedies include a reverse stock split.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-007621), on November 20, 2026, and is solely responsible for the information contained therein.